Recent 8-K filings for SCYX

• March 31, 2026, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 2.01item 7.01item 9.01 ◈ Material Agreements

  SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total

  Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.

• March 31, 2026, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 7.01item 8.01item 9.01 ◈ Material Agreements

  SCYNEXIS raises ~$40M in private placement; extends cash runway into mid-2029

  Gross proceeds of ~$40M from sale of 34.75M shares and 8.75M pre-funded warrants at $0.92 per unit; up to $52.2M additional if warrants exercised.

• October 15, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01

  SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment

  Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.

• June 26, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

  SCYNEXIS receives Nasdaq bid price deficiency notice; has until Dec 17 to regain compliance

  Received Nasdaq letter on June 20, 2025, for bid price <$1 for 30 consecutive business days.

• November 6, 2024, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  SCYNEXIS enters $50M at-the-market equity facility with Cantor Fitzgerald

  New Sales Agreement with Cantor allows sale of up to $50M of common stock at SCYNEXIS's option.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.47 · Most common event other_material

1 positive 1 negative 10 neutral

source · SCYX on sec.gov